Global X China MedTech ETF | 2841
1757843193
Hong Kong (SAR)
Our Products Research
Subscribe Search

Global X China MedTech ETF

2841 HKD

Invest in 2841

Important Information

Investors should not base investment decisions on this material alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

  • The investment objective of Global X China MedTech ETF (the “Fund”) is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China MedTech Index.
  • The Fund is exposed to concentration risk by tracking a single region or country.
  • The Index constituents may be concentrated in a specific industry or sector, which may potentially more volatile than a fund with a diversified portfolio.
  • Investment in Emerging Market, such as A-share market, may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.
  • The Stock Connect is subject to quota limitations. Where a suspension in the trading through the Stock Connect is effected, the Sub-Fund’s ability to invest in A-Shares or access Mainland China markets through the programme will be adversely affected.
  • Listed companies on the ChiNext market and/or STAR Board are usually subject to higher fluctuation in stock prices and liquidity risks, over-valuation risk, differences in regulation, delisting risk, and concentration risk.
  • There are risks and uncertainties associated with the current Mainland China tax laws, regulations and practice in respect of capital gains realized via Stock Connect on the Fund’s investments in Mainland China. Any increased tax liabilities on the Fund may adversely affect the Fund’s value.
  • The trading price of the Fund’s unit on the SEHK is driven by secondary market trading factors, which may lead to a substantial premium or discount to the Fund’s net asset value.
  • The Fund’s synthetic replication strategy may invest up to 50% of its net asset value in financial derivative instruments (“FDIs”), which may expose the Fund to counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. The Fund may suffer losses from its usage of FDIs.
  • The Manager may at its discretion pay dividends out of the capital of the Fund. Distributions paid out of capital, represent a return of an investor’s original investment or its gains and may potentially reduce the Fund’s Net Asset Value per Share as well as the capital available for future investment.
  • The Fund may suffer from a losses or delays when recovering the securities lent out. This may potentially affect its ability to meet payment and redemption obligations. Collateral shortfalls due to inaccurate pricing or change of value of securities lent, may cause significant losses to the Fund.

Why Global X China MedTech ETF? Product Flyer 

  • Medtech sector recorded weak performance in 2024 dragged by multiple headwind including lingering anti-corruption impact and gradual implementation of VBP. Sector could see recovery in 2025 as supported by stimulus program and a lower base in 2024, and we already see sequentially improving tender statistics.
  • MoF’s Buy China proposal should support accelerating import substitution, which bodes well for domestic leaders.
  • Export value to overseas market recorded stable growth despite geopolitical risks. AI offers optionality for medtech companies to enhance products and solutions.

Fund InformationAs of 11 Sep 2025

Fund Inception Date 03 Aug 2023
SEHK Listing Date 04 Aug 2023
Fiscal Year Ending 31 Mar
Ongoing Charges Over A Year ^ 0.68%
Distribution Frequency Annually (usually in May of each year) at the Manager’s discretion. *
NAV Per Share RMB $49.06
Fact Sheet
^ The Fund (Listed Class) adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. Click to learn more. * Dividend is not guaranteed, distributions may be made out of capital or income at the Manager’s discretion. Positive distribution does not imply positive return. Please refer to the IMPORTANT INFORMATION section above and the Fund’s prospectus for further details.

Index Information1As of 11 Sep 2025

Underlying Index Solactive China MedTech Index 2
Index Type Net Total Return
Base Currency RMB
Closing Level 1,230.74
Change 14.93
Change % 1.23%

Trading InformationAs of 11 Sep 2025

HKD Traded Units3
Exchange Hong Kong Stock Exchange
Stock Code 2841
ISIN HK0000945649
Board Lot Size 50 Units
Trading Currency HKD
Base Currency RMB
Total Net Asset Value $21,474,949.36
Outstanding Units 400,000

ETF Summary

The investment objective of the Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China MedTech Index (the “Index”).

Research

View More Related Research

ETF Prices

* Market prices are provided on a 15-minute delayed basis by ICE Data Services. (See terms and conditions)

Daily NAV per Unit5As of 11 Sep 2025

NAV Change % Change
Official NAV per Unit in RMB $49.06 $0.59 1.22%
NAV per Unit in HKD 3 $53.69 $0.65 1.22%

Performance As of 11 Sep 2025

Cumulative Return Fund NAV (%) Benchmark (%)
1 Mth 13.02 13.06
3 Mths 23.88 24.11
6 Mths 18.54 18.95
1 Yr 54.76 56.07
YTD 31.62 32.46
Since Inception -2.19 -0.64
Calendar Year Return Fund NAV (%) Benchmark (%)
2024 -16.90 -16.37
2023 - -
2022 - -
2021 - -
2020 - -
Source: Mirae Asset Global Investments (Hong Kong) Limited.
• Past performance information is not indicative of future performance. Investors may not get back the full amount invested.
• The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested.
• These figures show by how much the Fund increased or decreased in value during the calendar year shown.
• Performance data has been calculated in RMB including ongoing charges and excluding trading costs on SEHK you might have to pay.
• Where no past performance is shown there was insufficient data available in that year to provide performance.
• The Index of the Fund is Solactive China MedTech Index.
• Fund inception date: 3 Aug 2023

Exposure As of 29 Aug 2025

    Weight (%)
Health Care 77.8
Consumer Staples 22.1
Cash 0.1
    Weight (%)
China 99.9
Cash 0.1

Holdings Overview As of 11 Sep 2025

Total Net Asset Value (in HKD) Total Net Asset Value (in USD) Total Net Asset Value (in RMB) Number of Securities Securities (%) Cash and Cash Equivalent (%)
21,474,949.36 2,757,025.56 19,622,578.00 30 99.63 0.37

Daily HoldingsAs of 11 Sep 2025

Name of Securities Exchange Ticker Exchange Market Price (in RMB) Number of Shares Held Market Value (in RMB) Net Assets (%)
JD HEALTH INTERNATIONAL INC 6618 HK Hong Kong 62.86 36,032 2,265,088.62 11.54
ALIBABA HEALTH INFORMATION T 241 HK Hong Kong 6.58 285,998 1,881,498.53 9.59
SHANGHAI UNITED IMAGING HE 688271 C1 Shanghai 154.99 11,098 1,720,079.02 8.77
SHENZHEN MINDRAY BIO-MEDIC 300760 C2 Shenzhen 243.74 6,332 1,543,361.68 7.87
AIER EYE HOSPITAL GROUP 300015 C2 Shenzhen 13.12 112,176 1,471,749.12 7.50
IMEIK TECHNOLOGY DEVELOPME 300896 C2 Shenzhen 201.00 6,217 1,249,617.00 6.37
SHENZHEN NEW INDUSTRIES BI 300832 C2 Shenzhen 70.18 12,609 884,899.62 4.51
APT MEDICAL INC 688617 C1 Shanghai 309.53 2,183 675,703.99 3.44
JIANGSU YUYUE MEDICAL EQU 002223 C2 Shenzhen 39.57 16,448 650,847.36 3.32
PING AN HEALTHCARE AND TECHN 1833 HK Hong Kong 20.78 31,169 647,622.19 3.30
XTALPI HOLDINGS 2228 HK Hong Kong 9.34 66,864 624,383.82 3.18
GENSCRIPT BIOTECH CORP 1548 HK Hong Kong 15.48 33,593 519,960.78 2.65
LEPU MEDICAL TECHNOLOGY 300003 C2 Shenzhen 18.04 26,566 479,250.64 2.44
SHANDONG WEIGAO GP MEDICAL 1066 HK Hong Kong 5.21 75,062 390,933.94 1.99
MICROPORT SCIENTIFIC CORP 853 HK Hong Kong 12.43 30,178 375,005.60 1.91
AUTOBIO DIAGNOSTICS 603658 C1 Shanghai 41.72 8,875 370,265.00 1.89
IRAY GROUP 688301 C1 Shanghai 111.30 3,202 356,382.60 1.82
MEINIAN ONEHEALTH HEALTHCA 002044 C2 Shenzhen 5.29 65,011 343,908.19 1.75
BGI GENOMICS 300676 C2 Shenzhen 51.88 6,573 341,007.24 1.74
INTCO MEDICAL TECHNOLOGY C 300677 C2 Shenzhen 36.91 8,867 327,280.97 1.67
ANDON HEALTH 002432 C2 Shenzhen 39.54 7,370 291,409.80 1.49
JAFRON BIOMEDICAL 300529 C2 Shenzhen 24.19 11,997 290,207.43 1.48
MICRO-TECH NANJING 688029 C1 Shanghai 93.72 2,859 267,945.48 1.37
SHANGHAI CONANT OPTICAL 2276 HK Hong Kong 39.71 6,583 261,409.86 1.33
SONOSCAPE MEDICAL CORP 300633 C2 Shenzhen 36.55 7,014 256,361.70 1.31
OVCTEK CHINA INC 300595 C2 Shenzhen 18.13 13,672 247,873.36 1.26
EYEBRIGHT MEDICAL TECHNOLO 688050 C1 Shanghai 79.66 3,081 245,432.46 1.25
SHANGHAI MICROPORT ENDOVAS 688016 C1 Shanghai 110.69 1,824 201,898.56 1.03
SANSURE BIOTECH INC 688289 C1 Shanghai 20.58 9,137 188,039.46 0.96
SINOCARE INC 300298 C2 Shenzhen 21.00 8,613 180,873.00 0.92
Source: Mirae Asset, Bloomberg
Holdings are subject to change. Cash, where shown, includes other assets and liabilities, such as payables and receivables.
202509111.21841.2279879257451230.74

Tracking Difference / Error

Tracking Difference / Tracking Error

Tracking Difference
Tracking difference is the return difference between the Fund and the Underlying Index over a certain period of time.
Tracking Error
Tracking error measures how consistently the Fund follows the Underlying Index. It is the volatility (measured by standard deviation) of that return difference.

Tracking Difference (TD)

Fund Listing Date:4 Aug 2023

Estimated Annual TD: -2.00%

TD (Since Listing): N/A%

TD for Calendar Year 2024:-0.53%

Tracking Error (TE)

Fund Listing Date:4 Aug 2023

Rolling 1 Year TE^ :N/A%

^ Annualized based on the number of dealing days in the past year when daily TD is calculated.


Graph for Tracking Difference

ETFs performance is calculated on an NAV to NAV basis and assumes reinvestment of distribution.

Hover over the chart points for details

Market Makers 6

Flow Traders Hong Kong Limited

Mirae Asset Securities Co., Ltd.

Participating Dealers 7

BNP Paribas Securities Services

China Merchants Securities (HK) Co., Limited

Citigroup Global Markets Asia Limited

DBS Vickers (Hong Kong) Limited

Goldman Sachs (Asia) Securities Limited

Haitong International Securities Company Limited

Mirae Asset Securities (HK) Limited

Valuable Capital Limited

Back to Top

You’re now leaving Global X Hong Kong website


Clicking "Confirm" below will take you to an independent site. Information and services provided on this independent site are not reviewed by, guaranteed by, or Global X Hong Kong. This independent site's terms and conditions, privacy and security policies, or other legal information may be different from those of Global X Hong Kong’s site. Global X Hong Kong is not liable for any direct or indirect technical or system issues, consequences, or damages arising from your use of this independent website.



CancelConfirm

This website is intended for Hong Kong investors only. Your use of this website means you agree to our Terms of use. This website is strictly for informational purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. In 2018, Global X was acquired by Mirae Asset Global Investments and Mirae Asset Global Investments Co., Ltd. is the parent company of Mirae Asset Global Investments (Hong Kong) Limited.

The information contained in this website is for information purposes only and does not, constitute any recommendations, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Product will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance.

Before making any investment decision to invest in the Product, investors should read the Product’s prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Product and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments.

Certain information contained in this website is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited (“Mirae Asset HK”), the Manager of the Product, has, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. Mirae Asset HK accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.

The Products are not sponsored, endorsed, issued, sold or promoted by their index providers. For details of an index provider including any disclaimer, please refer to the relevant Product’s offering documents.

The contents of this website is prepared and maintained by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.